TY - JOUR
T1 - KlebPhaCol
T2 - a community-driven resource for Klebsiella research identified a novel phage family
AU - Rothschild-Rodriguez, Daniela
AU - Lambon, Kai S
AU - Kushwaha, Simran Krishnakant
AU - Garushyants, Sofya K
AU - Ertelt, Moritz
AU - Latka, Agnieszka
AU - Costa, Ana Rita
AU - Mantzouratou, Anna
AU - King, Claire
AU - Boeckaerts, Dimitri
AU - Sheridan, Elizabeth
AU - Koonin, Eugene V
AU - Merrick, Francesca
AU - Drobniewski, Francis
AU - De Angelis, Ilaria
AU - Saeed, Kordo
AU - Martin, Macy
AU - Sutton, J Mark
AU - Wand, Matthew E
AU - Andrew, Michael
AU - Hedges, Morgen
AU - Brouns, Stan J J
AU - Haas, Pieter-Jan
AU - Lawson, Sophie T
AU - Fordham, Stephen M E
AU - Lee, Yan-Jiun
AU - Wu, Yi
AU - Briers, Yves
AU - Braun, Peter
AU - Weigele, Peter R
AU - Nobrega, Franklin L
N1 - Publisher Copyright:
© 2025 The Author(s). Published by Oxford University Press.
PY - 2025/11/26
Y1 - 2025/11/26
N2 - The growing threat of multidrug-resistant Klebsiella pneumoniae, coupled with its role in gut colonisation, has intensified the search for new treatments, including bacteriophage therapy. Despite increasing documentation of Klebsiella-targeting phages, clinical applications remain limited, with key phage-bacteria interactions still poorly understood. A major obstacle is fragmented access to well-characterised phage-bacteria pairings, restricting the collective advancement of therapeutic and mechanistic insights. To address this gap, we created the Klebsiella Phage Collection (KlebPhaCol), an open resource comprising 52 phages and 74 Klebsiella isolates, characterised at phenotypic and genomic levels. These phages span six families-including a novel family, Felixviridae, associated with the human gut-and target 20 sequence types (including ST258, ST11, and ST14) and 19 capsular-locus types (including KL1 and KL2), across 6 Klebsiella species. Freely accessible at www.klebphacol.org, KlebPhaCol invites the scientific community to both use and contribute to this resource, fostering collaborative research and a deeper understanding of Klebsiella-phage interactions beyond therapeutic use.
AB - The growing threat of multidrug-resistant Klebsiella pneumoniae, coupled with its role in gut colonisation, has intensified the search for new treatments, including bacteriophage therapy. Despite increasing documentation of Klebsiella-targeting phages, clinical applications remain limited, with key phage-bacteria interactions still poorly understood. A major obstacle is fragmented access to well-characterised phage-bacteria pairings, restricting the collective advancement of therapeutic and mechanistic insights. To address this gap, we created the Klebsiella Phage Collection (KlebPhaCol), an open resource comprising 52 phages and 74 Klebsiella isolates, characterised at phenotypic and genomic levels. These phages span six families-including a novel family, Felixviridae, associated with the human gut-and target 20 sequence types (including ST258, ST11, and ST14) and 19 capsular-locus types (including KL1 and KL2), across 6 Klebsiella species. Freely accessible at www.klebphacol.org, KlebPhaCol invites the scientific community to both use and contribute to this resource, fostering collaborative research and a deeper understanding of Klebsiella-phage interactions beyond therapeutic use.
KW - Bacteriophages/genetics
KW - Genome, Viral
KW - Humans
KW - Klebsiella Infections/microbiology
KW - Klebsiella pneumoniae/virology
KW - Klebsiella/virology
KW - Phylogeny
U2 - 10.1093/nar/gkaf1122
DO - 10.1093/nar/gkaf1122
M3 - Article
C2 - 41261852
SN - 0305-1048
VL - 53
JO - Nucleic acids research
JF - Nucleic acids research
IS - 21
M1 - gkaf1122
ER -